论文部分内容阅读
目的探讨吉西他滨联合替吉奥胶囊化疗方案与吉西他滨单药治疗进展期胰腺癌的疗效。方法对2008年1月至2011年1月收治的52例晚期胰腺癌患者的临床资料进行回顾性分析,其中28例采用吉西他滨联合替吉奥胶囊方案治疗(A组);24例采用吉西他滨单药治疗(B组)。采用Kaplan-Meier法分析患者的生存时间,并比较两组患者的客观缓解率、临床受益反应(CBR)、中位疾病进展时间、中位生存时间和不良反应。结果 A组有效率明显高于B组(32.1%vs.20.8%),差异有统计学意义(P=0.039)。A组疾病控制率(DCR)高于B组(67.9%vs.45.8%),但差异无统计学意义(P=0.230)。A组患者CBR缓解率高于B组(72.1%vs.46.9%),差异无统计学意义(P=0.41)。A组的中位生存时间为10.2个月(95%CI:8.0～11.8个月),高于B组的8.03个月(95%CI:3.8～10.9个月),差异有统计学意义(P=0.045);A、B两组的中位疾病进展时间分别为3.6个月和3.0个月(P=0.721)。A组的6个月生存率(72.7%)略高于B组(66.8%),但差异无统计学意义(P>0.05)。两组不良反应的发生率也相似(P>0.05)。结论吉西他滨联合替吉奥胶囊治疗方案与单药治疗晚期胰腺癌相比,在客观疗效、中位生存时间表现出一定优势,疾病控制率及临床受益反应也有所提高,且不良反应可耐受,是晚期胰腺癌的有效治疗方案。
Objective To investigate the curative effect of gemcitabine combined with tioguan capsule chemotherapy and gemcitabine monotherapy on advanced pancreatic cancer. Methods The clinical data of 52 patients with advanced pancreatic cancer admitted to our hospital from January 2008 to January 2011 were retrospectively analyzed. Among them, 28 cases were treated with gemcitabine and tigeorgile capsules (group A); 24 cases were treated with gemcitabine monotherapy Treatment (Group B). Survival time was analyzed by Kaplan-Meier method. The objective response rate, clinical benefit response (CBR), median disease progression time, median survival time and adverse reactions were compared between the two groups. Results The effective rate of group A was significantly higher than that of group B (32.1% vs. 20.8%), the difference was statistically significant (P = 0.039). The disease control rate (DCR) in group A was higher than that in group B (67.9% vs.45.8%), but the difference was not statistically significant (P = 0.230). The response rate of CBR in group A was higher than that in group B (72.1% vs 46.9%), with no significant difference (P = 0.41). The median survival time in group A was 10.2 months (95% CI: 8.0-11.8 months), which was significantly higher than that in group B (8.03 months, 95% CI: 3.8-10.9 months) (P = 0.045). The median time to disease progression in groups A and B were 3.6 months and 3.0 months, respectively (P = 0.721). The 6-month survival rate (72.7%) in group A was slightly higher than that in group B (66.8%), but the difference was not statistically significant (P> 0.05). The incidence of adverse reactions in both groups was similar (P> 0.05). Conclusion The combination of gemcitabine and tegaserod capsule has shown some advantages in terms of objective curative effect and median survival time as compared with monotherapy in the treatment of advanced pancreatic cancer. The rate of disease control and clinical benefit response also increased, and adverse reactions were tolerable. Is an effective treatment of advanced pancreatic cancer.